Press Releases :: Moleculin Biotech, Inc. (MBRX)

Moleculin Announces First Patients Treated in European Annamycin Clinical Trial

Mar 14, 2019

Moleculin Files with FDA for Expedited Approval Pathway for Annamycin

Mar 13, 2019

Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2018

Feb 21, 2019

Moleculin Announces Outlicensing Deal To Accelerate Preclinical and Clinical Development

Feb 20, 2019

Moleculin Announces Approval for Third Drug to Commence Clinical Trials

Feb 7, 2019

Moleculin Announces the FDA has Granted Orphan Drug Designation for its Brain Tumor Drug

Feb 5, 2019

Moleculin Announces Dr. James L. Abbruzzese, Chief of Medical Oncology Division at Duke University, Joins Science Advisory Board

Jan 17, 2019

Moleculin Announces Patient Recruitment Begins in Annamycin Clinical Trial In Poland

Jan 9, 2019

Moleculin Announces Positive Data for its Pancreatic Cancer Drug Candidate

Jan 3, 2019

REMINDER: Moleculin Announces Conference Call to Discuss Recent Breakthrough Discovery and FDA Filing on Wednesday, December 12, 2018

Dec 11, 2018